Email this article Oxazoline derivatives of [17(20)E]-21-norpregnene – inhibitors of CYP17A1 activity and proliferation of prostate carcinoma cells
- Authors: Kostin V.A.1, Latysheva A.S.1, Zolottsev V.A.1, Tkachev Y.V.2, Timofeev V.P.2, Kuzikov A.V.1, Shumyantseva V.V.1, Morozevich G.E.1, Misharin A.Y.1
-
Affiliations:
- V. N. Orekhovich Research Institute of Biomedical Chemistry, Russian Academy of Medical Sciences
- V. A. Engel’gardt Institute of Molecular Biology, Russian Academy of Sciences
- Issue: Vol 67, No 4 (2018)
- Pages: 682-687
- Section: Full Article
- URL: https://journals.rcsi.science/1066-5285/article/view/242433
- DOI: https://doi.org/10.1007/s11172-018-2122-7
- ID: 242433
Cite item
Open Access
Access granted
Subscription Access
Abstract
Nine new oxazolinyl derivatives of [17(20)E]-21-norpregnene, differing in the structure of steroid moiety, were investigated for their potency to inhibit the CYP17A1 catalytic activity, as well as growth and proliferation of LNCaP and PC-3 prostate carcinoma cell lines. The activity of one of the investigated compounds, 2´-{[(E)3β-hydroxyandrost-5-en-17-ylidene]methyl}-4´,5´-dihydro-1´,3´-oxazole (1), was found to be comparable with that of Abiraterone, a known inhibitor of CYP17A1 used for treatment of prostate cancer. A model of the interaction of oxazoline 1 with the active site of CYP17A1 was constructed by the molecular dynamics method. A correlation was found between the structure and the biological activity in the series of [17(20)E]-21-norpregnene oxazolinyl derivatives.
About the authors
V. A. Kostin
V. N. Orekhovich Research Institute of Biomedical Chemistry, Russian Academy of Medical Sciences
Email: vazolottsev@mail.ru
Russian Federation, Build. 8, 10 Pogodinskaya ul., Moscow, Russian Federation, 119121
A. S. Latysheva
V. N. Orekhovich Research Institute of Biomedical Chemistry, Russian Academy of Medical Sciences
Email: vazolottsev@mail.ru
Russian Federation, Build. 8, 10 Pogodinskaya ul., Moscow, Russian Federation, 119121
V. A. Zolottsev
V. N. Orekhovich Research Institute of Biomedical Chemistry, Russian Academy of Medical Sciences
Author for correspondence.
Email: vazolottsev@mail.ru
Russian Federation, Build. 8, 10 Pogodinskaya ul., Moscow, Russian Federation, 119121
Ya. V. Tkachev
V. A. Engel’gardt Institute of Molecular Biology, Russian Academy of Sciences
Email: vazolottsev@mail.ru
Russian Federation, 32 ul. Vavilova, Moscow, Russian Federation, 119991
V. P. Timofeev
V. A. Engel’gardt Institute of Molecular Biology, Russian Academy of Sciences
Email: vazolottsev@mail.ru
Russian Federation, 32 ul. Vavilova, Moscow, Russian Federation, 119991
A. V. Kuzikov
V. N. Orekhovich Research Institute of Biomedical Chemistry, Russian Academy of Medical Sciences
Email: vazolottsev@mail.ru
Russian Federation, Build. 8, 10 Pogodinskaya ul., Moscow, Russian Federation, 119121
V. V. Shumyantseva
V. N. Orekhovich Research Institute of Biomedical Chemistry, Russian Academy of Medical Sciences
Email: vazolottsev@mail.ru
Russian Federation, Build. 8, 10 Pogodinskaya ul., Moscow, Russian Federation, 119121
G. E. Morozevich
V. N. Orekhovich Research Institute of Biomedical Chemistry, Russian Academy of Medical Sciences
Email: vazolottsev@mail.ru
Russian Federation, Build. 8, 10 Pogodinskaya ul., Moscow, Russian Federation, 119121
A. Yu. Misharin
V. N. Orekhovich Research Institute of Biomedical Chemistry, Russian Academy of Medical Sciences
Email: vazolottsev@mail.ru
Russian Federation, Build. 8, 10 Pogodinskaya ul., Moscow, Russian Federation, 119121
